{
  "market_name": "Aspergillosis Treatment Market",
  "unit": "Billion",
  "cagr": 16.3,
  "value_2024": 12.5,
  "value_2033": 48.65,
  "REGIONAL_RANKING": {
    "first": "North America",
    "second": "Europe",
    "third": "Asia Pacific"
  },
  "EUROPE_COUNTRY_CLASSIFICATION": {
    "Germany": "dominant",
    "United Kingdom": "fastest_growing",
    "France": "emerging"
  },
  "SEGMENTS": {
    "Infection Type": [
      "Allergic Aspergillosis",
      "Chronic Aspergillosis",
      "Invasive Aspergillosis"
    ],
    "Drug Class": [
      "Antifungal Drugs",
      "Corticosteroids",
      "Others"
    ],
    "Route of Administration": [
      "Oral",
      "Intravenous",
      "Inhaled Dry-Powder",
      "Others"
    ],
    "Distribution Channel": [
      "Hospital Pharmacy",
      "Retail Pharmacy",
      "Online Pharmacy"
    ],
    "Patient Category": [
      "Hematopoietic Stem-Cell Transplant",
      "Solid-Organ Transplant",
      "ICU / Critical-Care Patients",
      "COPD & Severe Asthma Patients",
      "Others"
    ]
  }
}